triplet question

Quick question for people doing the triplet therapy (BRAF/MEK inhibitor; PD-L1).  Did you have progression beforehand with PD immunotherapy, or did you go directly to the triplet?  I was under the impression that everyone (or pretty much everyone) did the single agent first, and then eventually (probably after ipi/nivo) moved on to the triplet if they were BRAF positive. I’m asking because my next treatment plan was supposed to be zelboraf/cotellic, followed eventually with tecentriq, but I just got a letter from my insurance company saying that they had denied tecentriq because I progressed on a similar medication (opdivo).  Like I said, I thought (perhaps incorrectly) that that was pretty much the case with everyone doing the triplet, and that the hope was that the combo of the three would have better results than opdivo alone.

Thanks for your feedback.

PS: That zelboraf/cotellic combo really kicked my rear.  Was pretty uneventful for the first 8 or 9 days, and then – bam – in the hospital for 5 days, with high fever, rash on every bit of skin from ankles to shoulders, pretty much every secondary effect listed in their brochure.  Doc dialed back both of them a bit and added prednisone, which I’m almost off now.  Still lots of secondary effects, but more manageable.  Was really hoping to get on the tecentriq to see what that would do after the targeted, but now that sounds in jeopardy. 🙁